


GW Pharmaceuticals (NASDAQ:GWPH)

What were the client’s needs and how did Edison meet them?

“GW Pharmaceuticals wanted to expand its profile internationally, particularly with North American and European investors. They also needed a more rounded approach to the assessment of their product pipeline to ensure the market fully appreciated the value of their underlying technology platform. GW Pharmaceuticals has worked with Edison for over 5 years and in that time the company has raised \$214m and seen a substantial increase in liquidity and market capitalization”

Edison value impact



Key Performance Metrics	
31680	Number of investors tracked reading reports
363%	Increase in Share Liquidity
388%	Increase in Share Price
\$214M	Capital raised since initiation report
64	Number of Countries reading research

Number of Tracked Readers Investing in GW Pharmaceuticals		
Sabby	OppenheimerFunds	RBC Global AM
Sphera	Barclays PLC	Capital World
Lazard	Citigroup Inc	Deutsche Bank AG
PNC	Columbia Mgmt IA	Parametric Portfolio
BlackRock	Alliance Bernstein L.P	Fiera Capital

“GW Pharmaceuticals engages Edison to ensure a balanced and accurate investment case for our business is made available to all investors worldwide. We particularly value Edison’s long-term approach to assessing the investment case for our business and the broad availability of their research.”

**Steve Shultz, VP Investor Relations
GW Pharmaceuticals**

“The value to GW Pharmaceuticals is ensuring that US investors gain exposure to Edison’s high quality research via a product specifically tailored to their needs.”

**Justin Gover, CEO
GW Pharmaceuticals PLC**

Market cap now:	\$1.8B
Market cap at initiation:	\$118M
Increase in value	\$1.7B

